The clinical efficacy of pemetrexed in the treatment of patients with non-small cell lung cancer, especially those with high Akt kinase activity and Cdk2/Cyclin-A expression, is worthy of further investigation. This evidence concerns the gene CDK2 and non-small cell lung carcinoma.